Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PDE6D | O43924 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.58 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187206 | 0.89 | ALOX5AP (0.69) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3968179 | 0.89 | HDAC1 (0.62) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL10040276 | 0.89 | ALOX5AP (0.69) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3970223 | 0.88 | HDAC1 (0.64) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3970228 | 0.88 | HDAC1 (0.64) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3969090 | 0.86 | HDAC1 (0.76) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3403890 | 0.86 | LMNA (0.65) | MEN1KMT2ANPSR1LMNAGAA | |
| SCHEMBL3235521 | 0.85 | MEN1 (0.61) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3494747 | 0.85 | MEN1 (0.61) | MEN1KMT2AHDAC1HDAC6ALOX5AP | |
| SCHEMBL3975956 | 0.84 | HDAC1 (0.63) | MEN1KMT2AHDAC1HDAC6ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9885883-B2 | Optical element for correcting color blindness | NITTO DENKO CORPORATION (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9885883-B2 | Optical element for correcting color blindness | NITTO DENKO CORPORATION (JP) | 2018-02-06 | — | — | US | disclosed |
| US-20160085090-A1 | OPTICAL ELEMENT FOR CORRECTING COLOR BLINDNESS | NITTO DENKO CORPORATION (JP) | 2016-03-24 | — | — | US | disclosed |
| US-8808879-B2 | Phototherapy devices and methods comprising substituted carbazole compounds | NITTO DENKO CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8586205-B2 | Compounds for organic light emitting diode emissive layers | NITTO DENKO CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20120016449-A1 | PHOTOTHERAPY DEVICES AND METHODS COMPRISING SUBSTITUTED CARBAZOLE COMPOUNDS | NITTO DENKO CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016449-A1 | PHOTOTHERAPY DEVICES AND METHODS COMPRISING SUBSTITUTED CARBAZOLE COMPOUNDS | NITTO DENKO CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
| US-20110062386-A1 | COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE EMISSIVE LAYERS | NITTO DENKO CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-7655624-B2 | Antiinflammatory agents; osteoporosis; cardiovascular disorders; coating for prosthetics | BIOMET DEUTSCHLAND GMBH (DE) | 2010-02-02 | — | — | US | disclosed |
| US-7276482-B2 | Peptide and peptide mimetic derivatives with integrin-inhibitors properties II | BIOMET DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016449-A1 | PHOTOTHERAPY DEVICES AND METHODS COMPRISING SUBSTITUTED CARBAZOLE COMPOUNDS | TYR, PPOX, CRY1 | MEN1 2684/4885KMT2A 710/4885HDAC1 655/4885 |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | MEN1 2708/4885KMT2A 1542/4885HDAC1 743/4885 |
| US-20110062386-A1 | COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE EMISSIVE LAYERS | ALOX12, ALOX15B, ALOX15 | MEN1 1773/4885KMT2A 1816/4885HDAC1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.